Good afternoon Dr. Patel,

We are in receipt of your 8/30/2021, PMR/PMC Correspondence Status Update submission, to your COMIRNATY BLA. This submission notified the BLA of the submission of study protocols to the IND for [PMR# 4, Study C4591009] and [PMC# 12, Study C4591012].

Please note, in the BLA Approval Letter, all of the PMRs and PMCs have been designated a sequential, specific PMR# or PMC#. For example:

**POSTMARKETING REQUIREMENTS UNDER SECTION 505(o)**

4. Study C4591009, entitled “A Non-Interventional Post-Approval Safety Study of the Pfizer-BioNTech COVID-19 mRNA Vaccine in the United States,” to evaluate the occurrence of myocarditis and pericarditis following administration of COMIRNATY.

We acknowledge the timetable you submitted on August 21, 2021, which states that you will conduct this study according to the following schedule:

- Final Protocol Submission: August 31, 2021
- Monitoring Report Submission: October 31, 2022
- Interim Report Submission: October 31, 2023
- Study Completion: June 30, 2025
- Final Report Submission: October 31, 2025

**POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B**


- Final Protocol Submission: January 29, 2021
- Study Completion: June 30, 2023
- Final Report Submission: December 31, 2023

In your future correspondence, to the BLA and to the IND, please refer to the specific PMR # or PMC# to which the information pertains. This will mitigate confusion and maintain clarity of studies being discussed.

Please feel free to contact me via email if you have any questions.

Kind regards,

Helen
Helen Sullivan Gemignani
OVRR PMR/PMC Coordinator
RMSB/DVRPA
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research
U.S. Food and Drug Administration

Tel: 301 796-2640
helen.gemignani@fda.hhs.gov

This message is intended only for the use of the party to whom it is addressed and may contain information that is privileged, confidential, and protected from disclosure under law. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender immediately by e-mail or phone.